Reconversion of fosphenytoin in the presence of intestinal alkaline phosphatase.
TenHoor
C N
CN
Department of Pharmacokinetics and Drug Metabolism, Parke-Davis Research Division, Warner-Lambert Co., Ann Arbor, Michigan 48105, USA.
Stewart
B H
BH
D000469:Alkaline Phosphatase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D000927:Anticonvulsants / Q000378:metabolism* / Q000493:pharmacokinetics; D001711:Biotransformation; D003106:Colon / Q000201:enzymology; D066298:In Vitro Techniques; D007413:Intestinal Mucosa / Q000201:enzymology; D007422:Intestines / Q000201:enzymology*; D007583:Jejunum / Q000201:enzymology; D007700:Kinetics; D008297:Male; D009596:Nitrophenols / Q000378:metabolism; D009943:Organophosphorus Compounds / Q000378:metabolism; D010672:Phenytoin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics; D011355:Prodrugs / Q000378:metabolism* / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar
D000927:Anticonvulsants; D009596:Nitrophenols; D009943:Organophosphorus Compounds; D011355:Prodrugs; C008644:nitrophenylphosphate; D010672:Phenytoin; C043114:fosphenytoin; D000469:Alkaline Phosphatase